Elevated serum amyloid A is associated with venous thromboembolism

• References

• 1 Johnson BD, Kip KE, Marroquin OC. et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732.
• 2 Ridker PM, Hennekens CH, Buring JE. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 2000; 342: 836-843.
• 3 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
• 4 Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 451-457.
• 5 Di Minno MN, Tufano A, Ageno W. et al. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2012; 07: 9-13.
• 6 Rodriguez AL, Wojcik BM, Wrobleski SK. et al. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012; 33: 371-382.
• 7 Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-365.
• 8 Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30: 1672-1678.
• 9 Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
• 10 Takata S, Wada H, Tamura M. et al. Kinetics of c-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times. Biomarkers 2011; 16: 530-535.
• 11 van Rooijen M, Hansson LO, Frostegård J. et al. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 04: 77-82.
• 12 Jylhävä J, Haarala A, Eklund C. et al. Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. J Intern Med 2009; 266: 286-295.
• 13 Kumon Y, Suehiro T, Itahara T. et al. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 1994; 27: 469-473.
• 14 He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572-1581.
• 15 Lee MS, Yoo SA, Cho CS. et al. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006; 177: 5585-5594.
• 16 Cai H, Song C, Endoh I. et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007; 178: 1852-1860.
• 17 Zhao Y, Zhou S, Heng CK. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 1645-1650.
• 18 Ames PRJ, Antinolfi I, Ciampa A. et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease?. Rheumatology 2008; 47: 1832-1837.
• 19 Deguchi H, Pecheniuk NM, Elias DJ. et al. High density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
• 20 Pecheniuk NM, Elias DJ, Deguchi H. et al. Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost 2008; 100: 224-228.